Investor FAQ

If you are interested in Ionis Pharmaceuticals' investment details, you can find the answers to some frequently asked questions below.

  1. Where are you located?
  2. Can you provide a brief description of your Company?
  3. When was the Company founded and when did it go public?
  4. What is Ionis stock symbol and on what exchange is it traded?
  5. How many shares are outstanding?
  6. How can I purchase shares?
  7. How can I get a copy of your annual report?
  8. I have lost my stock certificates. How can I replace them?

Where are you located?
Ionis Pharmaceuticals, Inc.
2855 Gazelle Court
Carlsbad, CA 92010
(Carlsbad is approximately 35 miles north of downtown San Diego.)
Back to top
Can you provide a brief description of your Company?
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over 45 drugs in development. SPINRAZA® (nusinersen) has been approved in global markets for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. TEGSEDI (inotersen) and WAYLIVRA (volanesorsen) are two antisense drugs that Ionis discovered and successfully advanced through Phase 3 studies.  TEGSEDI is approved in the E.U. for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis, or hATTR, and is currently under regulatory review in the U.S. and Canada. WAYLIVRA is under regulatory review for marketing approval in the U.S., EU and Canada for the treatment of patients with familial chylomicronemia syndrome, or FCS. WAYLIVRA is also in a Phase 3 study in patients with familial partial lipodystrophy, or FPL. Akcea Therapeutics, an affiliate of Ionis focused on developing and commercializing drugs to treat patients with serious and rare diseases, will be responsible for commercializing TEGSEDI and WAYLIVRA. Ionis' patents provide strong and extensive protection for its drugs and technology.
Back to top
When was the Company founded and when did it go public?
Ionis Pharmaceuticals, Inc. was founded in 1989. Ionis conducted its initial public offering two years later in 1991.
Back to top
What is Ionis stock symbol and on what exchange is it traded?
Ionis is traded on the NASDAQ stock exchange under the symbol IONS. Please note that prior to December 22, 2015 our symbol was ISIS and prior to February 21, 2002 our symbol was ISIP.
Back to top
How many shares are outstanding?
The number of shares of voting common stock outstanding as of July 31, 2018 was 137,273,907.
Back to top
How can I purchase shares?
To purchase Ionis stock you may use the broker of your choice. Ionis does not offer a direct stock purchase plan.
Back to top
How can I get a copy of your annual report?
To view a PDF file of the annual reports from 2015-2017  click here. If you would like to receive a hard copy of any of Ionis' annual reports, please click here. Please note that if you are requesting that we send the annual report to an address outside of the U.S. (including Canada and Mexico) you must include your telephone number. The US Postal Service requires a phone number for shipments out of the U.S.
Back to top
I have lost my stock certificates. How can I replace them?
Contact our Transfer Agent, American Stock Transfer & Trust Company: American Stock Transfer & Trust Company (AST)
59 Maiden Lane
Plaza Level
New York, NY 10038
ATTN: Shareholder Services
Tel 1-800-937-5449
Tel 1-718-921-8206
http://www.amstock.com/main/ To begin the process, click here:
https://secure.amstock.com/shareholder/sh_login.asp
Back to top
©1999 - 2017 Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals, Inc.